Follicum AB Announces more than 50% Recruitment Reached In FOL-005 Phase IIa Hair Growth Study
Follicum AB (“Follicum” or “the Company”) today announced that more than half of the patients in the new Phase IIa clinical trial with FOL-005 for stimulating hair growth have been recruited. In the trial conducted at the Clinical Research Center for Hair and Skin Science (“CRC”) in Berlin and Bioskin, Hamburg, Germany, 60 patients with hair loss will be included. The trial investigates the safety and effect of different doses of the drug candidate FOL-005 on scalp.FOL-005 is a modified, short version of the endogenous protein, osteopontin. In the recently completed phase I/IIa study, FOL-